GlaxoSmithKline to divest cancer drugs in multibillion-deal with Novartis

GlaxoSmithKline is selling off its oncology business to Novartis for up to $16 billion as part of a three-pronged deal that also involves the two companies' consumer health care and vaccines businesses...